SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw an uptick in trading volume on Wednesday. 12,230,612 shares traded hands during mid-day trading, an increase of 46% from the average daily volume of 8,360,633 shares. The stock last traded at $19.7250 and had previously closed at $19.15.
More SELLAS Life Sciences Group News
Investors following SLS have been watching these news items:
- Positive Sentiment: SELLAS said its pivotal REGAL trial of galinpepimut-S (GPS) in a specific group of patients with acute myeloid leukemia met its primary endpoint. GPS was associated with a 41% lower risk of death and median overall survival of 24 months, versus 14.7 months with best available treatment; the company also reported no new safety signals. SELLAS REGAL trial announcement
- Neutral Sentiment: SLS also moved above its 200-day moving average, a technical milestone that may attract investor attention but does not establish a fundamental outlook. SLS moving-average article
- Negative Sentiment: The results are topline data, with further analyses still underway. FDA agreement, filing timing and eventual approval remain uncertain, and the trial focused on a defined, high-risk AML population. Analysis of REGAL results
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. Alliance Global Partners restated a "buy" rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $10.00.
Read Our Latest Report on SELLAS Life Sciences Group
SELLAS Life Sciences Group Stock Performance
The firm's 50 day simple moving average is $11.01 and its 200 day simple moving average is $8.87. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of -100.06 and a beta of 2.73.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05).
Hedge Funds Weigh In On SELLAS Life Sciences Group
Institutional investors have recently modified their holdings of the stock. Nykredit A S purchased a new stake in SELLAS Life Sciences Group in the 2nd quarter worth approximately $27,000. GAMMA Investing LLC grew its stake in shares of SELLAS Life Sciences Group by 293.2% during the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock worth $27,000 after purchasing an additional 1,630 shares during the period. California State Teachers Retirement System grew its stake in shares of SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock worth $39,000 after purchasing an additional 1,709 shares during the period. Wealthfront Advisers LLC acquired a new stake in shares of SELLAS Life Sciences Group during the 1st quarter worth approximately $48,000. Finally, Principal Financial Group Inc. purchased a new position in shares of SELLAS Life Sciences Group during the 1st quarter valued at approximately $53,000. Hedge funds and other institutional investors own 17.38% of the company's stock.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.